Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1644
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17289613 | NANOBODY-GLYCAN MODIFYING ENZYME FUSION PROTEINS AND USES THEREOF | Non-Final OA | President and Fellows of Harvard College |
| 17441183 | CLAUDIN-6 BISPECIFIC ANTIBODIES | Non-Final OA | The Regents of the University of California |
| 17422591 | COMPOSITIONS AND METHODS FOR MODULATING CELLULAR INTERNALIZATION | Final Rejection | The Regents of the University of California |
| 17258741 | PREVENTION OR TREATMENT METHOD FOR PERIPHERAL NEUROPATHY OR PAIN ACCOMPANYING DISEASE IN WHICH PERIPHERAL NEUROPATHY OR ASTROCYTE DISORDER IS RECOGNIZED | Non-Final OA | MITSUBISHI TANABE PHARMA CORPORATION |
| 17264386 | DOSING REGIMEN FOR BCMA-CD3 BISPECIFIC ANTIBODIES | Final Rejection | AMGEN INC. |
| 17618360 | ANTIBODIES AGAINST PD-1 AND METHODS OF USE THEREOF | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18969940 | ANTI-PSMA ANTIBODY CONJUGATES | Non-Final OA | ADC THERAPEUTICS SA |
| 18753316 | ANTIBODY MOLECULES AND CONJUGATES | Non-Final OA | ASTRAZENECA AB |
| 17491813 | EVALUATION AND TREATMENT OF BRADYKININ-MEDIATED DISORDERS | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18266993 | CAR-INKT WITH HIGH AMPLIFICATION, SURVIVAL CAPACITY AND TUMOR KILLING EFFECT AND USE THEREOF | Non-Final OA | Beijing Gene Key Life Technology Co., Ltd. |
| 18020447 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS BY TARGETING IGSF8 | Non-Final OA | Shanghai XunBaiHui Biotechnology Co., LTD. |
| 17311193 | BRAIN TARGETED DRUG DELIVERY METHOD VIA SYNDECAN-3 | Non-Final OA | PHARMACOIDEA Kft |
| 17624467 | ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF | Final Rejection | Mythic Therapeutics, Inc. |
| 17681855 | Chimeric Antigen Receptor Targeting CD22 and CD19 and Application thereof | Final Rejection | Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences |
| 17290957 | BISPECIFIC ANTIBODY, PREPARATION METHOD THEREOF AND APPLICATION THEREOF | Non-Final OA | EXCYTE LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy